O'Connell Joseph P 4
4 · Odonate Therapeutics, Inc. · Filed Jan 5, 2021
Insider Transaction Report
Form 4
O'Connell Joseph P
Chief Medical Officer
Transactions
- Award
Common Stock
2020-12-31$16.32/sh+169$2,758→ 3,169 total - Award
Employee Stock Option (Right to Buy)
2020-12-31+169→ 169 totalExercise: $19.20Exp: 2030-12-31→ Common Stock (169 underlying)
Footnotes (2)
- [F1]These shares were acquired on 12/31/2020 through the Odonate Therapeutics, Inc. 2017 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
- [F2]The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel, Odonate's investigational product; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date.